Compare Dow Inc (DOW) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dow Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Dow Inc trades at $29.34 (market cap $20.59B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Dow Inc is far larger — about 21.2× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Dow Inc pays a 4.91% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dow Inc for 83 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| DOW | MRVI | |
|---|---|---|
Market Cap | $20.59B | $972.90M |
Volume | 5,540,746 | 4,325,710 |
Sector | Basic Materials | Health |
52-Week High | $41.87 | $9.00 |
52-Week Low | $20.95 | $2.83 |
Typical Hold Time | 83 Days | 0 Days |
Enterprise Value | $36.29B | $1.08B |
Dividend Yield | 4.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOW trades at $29.19, up 3.81% on the day, with a bearish technical signal and neutral oscillators. The company reported negative net income of -$2.62B in 2025, with declining revenue from $56.9B in 2022 to $40.0B in 2025. Recent earnings have beaten expectations, but profitability metrics like ROE (-7.86%) and net margin (-3.13%) remain weak. Analyst consensus is a $33.80 price target with mixed ratings (30.56% Buy, 55.56% Hold).
The outlook is cautious due to persistent margin pressures and high debt levels, though the dividend payout and earnings beats offer some stability. Risks include cyclical demand weakness and rising leverage, but the stock trades below consensus target, suggesting potential upside if operational improvements materialize.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dow Inc
Dow Inc is a diversified chemical manufacturing company. It combining science and technology to develop innovative solutions that are essential to human progress. Dow's portfolio is comprised of six global business units, organized into three operating segments: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings.
Read more on DOW →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
